Grifols Announces Capital Investment Plan of Euro 400 Million Over the Next Five Years

Grifols Announces Capital Investment Plan of Euro 400 Million Over the Next Five Years

October 30, 2007

Investment Plan 2008-2012

The Board of Directors has approved a plan for investing in
production and plasma collection facilities that will
position the Company as an industry leader for the
foreseeable future.

    BARCELONA, Spain, Oct. 30 /Xinhua-PRNewswire/ --
Grifols' Board of Directors, which met on October 23, 2007
in Los Angeles, California, has approved a euro 400 million
investment plan that will be carried out between now and the
year 2012. Among other things, the new investments will be
to increase capacity for plasma fractionation and
purification, as well as to increase plasma supply. 

    Within the scope of the approved investment plan, euro
230 million will be designated for ensuring growth in
production and sales during the 2008-2012 period, and the
remaining euro 170 million will support growth from 2013
onward. This will allow the company to prepare for
sustained growth over the next 8 to 10 years.

    In order to ensure growth through the year 2012,
Grifols will invest euro 230 million in its production
facilities in Spain and the USA.

    Investments to be made in the Spanish facilities
include euro 130 million for the construction of a new
fibrin glue (biological adhesive) production facility and
expansion of the albumin and coagulation factor VIII
purification areas. Albumin and coagulaton factor VIII are
two of the principal plasma proteins that Grifols markets.


    In the USA, euro 100 million will be invested in the
Los Angeles facilities for the completion of the
purification and sterile filling areas for coagulation
factors (such as Factor VIII), the opening of new plasma
collection centers and the construction of a new analytical
laboratory in Austin, Texas. This laboratory, which will be
located near Grifols existing US-based laboratory, will
allow the company to handle the growing amount of plasma
samples to be analyzed.  Additionally, the new laboratory
will serve the strategic purpose of providing Grifols an
alternate testing location.

    Forty-two percent (42%) of the 2008-2012 investment
plan will be set aside for ensuring growth after the year
2013.

    These investments, designated for ensuring Grifols'
growth from the year 2013 onward, will also be allocated to
the Spanish and US facilities. Sixty million Euros will be
invested in facilities located in Barcelona, Spain mainly
for the purpose of doubling current plasma fractionation
capacity from 2 million liters in 2007 to 4 million liters
in 2013. In the USA, the company will invest euro 110
million at its current location in Los Angeles, California
to build a new Flebogamma DIF(R) (IVIG) production
facility.  The new facility will be designed to match the
existing Flebogamma DIF(R) facility in Barcelona, Spain.
Grifols will also continue to expand the number of plasma
collection centers it owns and operates in the USA.

    The investment plan takes into account the fact that
biological production facilities require an average of five
years from the time the investment is approved to the time
regulatory authorizations (FDA, EMEA, etc.) are likely to
be obtained for the marketing of products.

    All of the engineering projects related to the
investments to be carried out at the various Grifols'
facilities have already been designed and will be executed
by Grifols Engineering S.A., a wholly owned subsidiary of
Grifols that designs, fabricates and installs custom
production equipment for the biologics industry.  

    Grifols' euro 400 million five-year investment plan is
expected to be funded with both internal and external
resources. 

    About Grifols

    Grifols is a Spanish holding company specializing in
the pharmaceutical-hospital industry, with a presence in
more than 90 countries. Since May of 2006 its shares have
been traded on the Spanish Stock Exchange (Mercado Continuo
Espanol) and it is included in the Spanish index of medium
capitalization firms (IBEX MEDIUM CAP). It is currently the
leading European company in the plasma therapies industry
and the fourth-largest producer in the world. In the coming
years, Grifols will leverage its market leadership as a
vertically integrated company through past and future
investments that will allow it to ensure its plasma supply
through 77 plasmapheresis centers located in the United
States, while at the same time expanding fractionating
capacity with production facilities in Barcelona and Los
Angeles, capable of meeting the growing market demand.


    For more information, please contact:

     Raquel Lumbreras
     Duomo Comunicacion
     Mobile: [phone]
     Email:  [e-mail] 

     Grifols Press Office
     Tel:    [phone]
     Fax:    [phone]